Our top pick for
Midatech Pharma plc is a biotechnology business based in the US. Midatech Pharma shares (MTP) are listed on the NASDAQ and all prices are listed in US Dollars. Midatech Pharma employs 65 staff and has a market cap (total outstanding shares value) of USD$29.6 million.
|52-week range||USD$0.862 - USD$4.48|
|50-day moving average||USD$2.4971|
|200-day moving average||USD$2.0953|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.848|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-7,169,000|
|Return on assets TTM||-32.28%|
|Return on equity TTM||-151.13%|
|Market capitalisation||USD$29.6 million|
TTM: trailing 12 months
There are currently 108,824 Midatech Pharma shares held short by investors – that's known as Midatech Pharma's "short interest". This figure is 1.3% up from 107,480 last month.
There are a few different ways that this level of interest in shorting Midatech Pharma shares can be evaluated.
Midatech Pharma's "short interest ratio" (SIR) is the quantity of Midatech Pharma shares currently shorted divided by the average quantity of Midatech Pharma shares traded daily (recently around 640141.17647059). Midatech Pharma's SIR currently stands at 0.17. In other words for every 100,000 Midatech Pharma shares traded daily on the market, roughly 170 shares are currently held short.
However Midatech Pharma's short interest can also be evaluated against the total number of Midatech Pharma shares, or, against the total number of tradable Midatech Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Midatech Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Midatech Pharma shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Midatech Pharma shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Midatech Pharma.
Find out more about how you can short Midatech Pharma stock.
We're not expecting Midatech Pharma to pay a dividend over the next 12 months.
Midatech Pharma's shares were split on a 1:5 basis on 3 March 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Midatech Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Midatech Pharma shares which in turn could have impacted Midatech Pharma's share price.
Over the last 12 months, Midatech Pharma's shares have ranged in value from as little as $0.862 up to $4.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Midatech Pharma's is 1.6957. This would suggest that Midatech Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.